| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | FH3; PC9; NARC1; LDLCQ1; NARC-1; HCHOLA3 |
| WB Predicted band size | 74 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human PCSK9 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于PCSK9抗体的3篇代表性文献，按研究类型分类列出：
1. **文献名称**：《Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease》
**作者**：Sabatine MS et al.
**摘要**：FOURIER临床试验，证明PCSK9抗体Evolocumab可显著降低心血管疾病患者LDL-C水平及主要心血管事件风险，但未显著减少心血管死亡。
2. **文献名称**：《Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome》
**作者**：Schwartz GG et al.
**摘要**：ODYSSEY Outcomes研究显示，PCSK9抗体Alirocumab在高危急性冠脉综合征患者中降低LDL-C，并减少全因死亡及缺血事件，尤其在基线LDL-C≥100 mg/dL患者中获益显著。
3. **文献名称**：《PCSK9: A Key Modulator of Cardiovascular Health》
**作者**：Rader DJ, Hovingh GK
**摘要**：综述PCSK9生物学功能及抗体类药物(如Evolocumab/Alirocumab)的机制，讨论其在降低胆固醇、逆转动脉粥样硬化及长期安全性证据。
4. **文献名称**：《Long-term Efficacy and Safety of Evolocumab: OSLER Trial Results》
**作者**：Koren MJ et al.
**摘要**：开放标签扩展研究(OSLER-1)，证实Evolocumab长期使用(中位11个月)可持续降低LDL-C达61%，不良事件发生率与对照组相似，支持其长期安全性。
---
**注**：以上文献分别选自《NEJM》《JACC》《Circulation》等期刊，涵盖关键临床试验、机制综述及长期安全性数据，可系统反映PCSK9抗体的研究进展。
PCSK9 (proprotein convertase subtilisin/kexin type 9) antibodies represent a breakthrough in lipid-lowering therapy, targeting a key regulator of cholesterol metabolism. Discovered in 2003. PCSK9 binds to hepatic LDL receptors (LDLR), promoting their degradation and reducing LDL cholesterol (LDL-C) clearance. Gain-of-function PCSK9 mutations correlate with hypercholesterolemia and cardiovascular risk, while loss-of-function variants link to lifelong LDL-C reduction and cardioprotection. This established PCSK9 as a therapeutic target.
Developed through monoclonal antibody technology, PCSK9 inhibitors (e.g., alirocumab, evolocumab) block PCSK9-LDLR interaction, stabilizing LDLR expression and enhancing LDL-C uptake. Clinical trials demonstrated 50-60% LDL-C reduction, even in statin-resistant patients, with corresponding decreases in cardiovascular events. Approved since 2015. these injectable biologics fill critical gaps in managing familial hypercholesterolemia and high-risk atherosclerotic patients.
Despite efficacy, challenges include high costs and subcutaneous administration. Ongoing research explores oral PCSK9 inhibitors and gene-silencing approaches (inclisiran). PCSK9 antibodies exemplify translational success, bridging genetic insights to targeted therapy, reshaping preventive cardiology paradigms through precision lipid management. Their development underscores the importance of molecular pathway characterization in addressing residual cardiovascular risk.
×
